Physicochemical Properties
| Molecular Formula | C25H44CLNO3 |
| Molecular Weight | 442.0748 |
| Exact Mass | 441.3 |
| CAS # | 1323151-45-6 |
| PubChem CID | 52953469 |
| Appearance | Light yellow to brown ointment |
| LogP | 6.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 16 |
| Heavy Atom Count | 30 |
| Complexity | 471 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | C[C@H](CCC12CC3CC(C1)CC(C3)C2)C(=O)NCCOCCOCCCCCCCl |
| InChi Key | FRQCQVUXVOJKTG-AXYUOHRYSA-N |
| InChi Code | InChI=1S/C25H44ClNO3/c1-20(6-7-25-17-21-14-22(18-25)16-23(15-21)19-25)24(28)27-9-11-30-13-12-29-10-5-3-2-4-8-26/h20-23H,2-19H2,1H3,(H,27,28)/t20-,21?,22?,23?,25?/m1/s1 |
| Chemical Name | (2R)-4-(1-adamantyl)-N-[2-[2-(6-chlorohexoxy)ethoxy]ethyl]-2-methylbutanamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In HEK293 cells expressing GFP-HaloTag2/Fz4-HaloTag2/GFP-HaloTag7 fusion protein, HyT36 (10 µM; 24 h) decreases the expression of GFP-HaloTag2/Fz4-HaloTag2 [1]. In HEK293 Flp-In cells expressing HA-EGFP-HaloTag2, HyT36 (10 µM; 2 h or 48 h) decreased EGFP expression and increased Hsp70 binding to the HA-EGFP-HaloTag2 fusion protein [3]. In HEK293 Flp-In cells expressing HA-EGFP-HaloTag2, HyT36 (50 nM; 24 h) lowers the amount of EGFP-HaloTag2 [3]. In NIH-3T3 cells expressing HA−HaloTag2−HRasG12V, HyT36 (1 µM; 4 d) decreases the expression of HA−HaloTag2−HRasG12V [ |
| Cell Assay |
Western Blot Analysis[1][3] Cell Types: HEK293 cells expressing GFP-HaloTag2/Fz4-HaloTag2/HA-EGFP-HaloTag2 or NIH-3T3 cells expressing HA−HaloTag2−HRasG12V. Tested Concentrations: 1 µM or 10 µM. Incubation Duration: 2 h, 24 h or 4 days. Experimental Results: diminished the expression of fusion proteins and increased the binding of Hsp70 and HA-EGFP-HaloTag2 fusion protein. |
| References |
[1]. Identification of hydrophobic tags for the degradation of stabilized proteins. Chembiochem. 2012 Mar 5;13(4):538-41. [2]. Poloxin-2HT+: changing the hydrophobic tag of Poloxin-2HT increases Plk1 degradation and apoptosis induction in tumor cells. Org Biomol Chem. 2019 Mar 20;17(12):3113-3117. [3]. A bidirectional system for the dynamic small molecule control of intracellular fusion proteins. ACS Chem Biol. 2013 Oct 18;8(10):2293-2300. |
Solubility Data
| Solubility (In Vitro) | DMSO: 100 mg/mL (226.21 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2621 mL | 11.3104 mL | 22.6209 mL | |
| 5 mM | 0.4524 mL | 2.2621 mL | 4.5242 mL | |
| 10 mM | 0.2262 mL | 1.1310 mL | 2.2621 mL |